ATX-GD-59 (1.6mg)
$82.50
For laboratory research use only. Not for human use.
- Lyophilized peptides should be reconstituted using proper aseptic laboratory technique.
- Reconstitution must be performed using Canlab-supplied Bacteriostatic Water and handled in accordance with generally accepted research practices.
- Warranty related to reconstitution, sterility or material integrity applies only when Canlab Bacteriostatic Water is used.
- Use of third-party diluents or deviation from the provided handling guidance voids any applicable warranty.
For full handling instructions and limitations, see the Peptide Reconstitution, Research Use Only section in our Product Warranty Policy Page →
Description
Introducing ATX-GD-59, a cutting-edge peptide-based therapy meticulously crafted for the management of Graves’ disease. With a molecular weight of 2529.26 and a molecular formula of C114H198N32O32, ATX-GD-59 surpasses research-grade benchmarks, highlighting our unwavering dedication to excellence and pioneering advancements.
ATX-GD-59 redefines medical paradigms through its innovative mode of action, engineered to emulate epitopes and effectively immobilize the leukocytes responsible for assaulting the thyroid. It obstructs the generation of anti-thyroid stimulating hormone receptor (TSHR) stimulatory antibodies, revolutionizing the approach beyond conventional treatments. This advanced strategy homes in on the immunological foundation of Graves’ disease, marking a transformative path in disease management brought forth by ATX-GD-59.
Additional Information
Benefits
Please review the complete product description and available supporting documentation for product-specific research information. This product is sold strictly for laboratory research use.
Mechanism of Action
Refer to the product description, certificate of analysis and applicable published research for product-specific information. No medical or therapeutic claims are made.
